| Christopher Gene Watson, PSYD | |
|
30200 Agoura Rd Ste 190, Agoura Hills, CA 91301-5431 | |
| (818) 981-7845 | |
| (818) 459-3787 |
| Full Name | Christopher Gene Watson |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 4 Years |
| Location | 30200 Agoura Rd Ste 190, Agoura Hills, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982052635 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 3389 (Oregon) | Secondary |
| 103TC0700X | Psychologist - Clinical | 33067 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jaime Elizabeth Medvene Phd A Professional Psychological Corpora | 7911063201 | 4 |
News Archive
A new device could help to relieve the pain and discomfort experienced by thousands of amputees as a result of poorly fitting replacement lower limbs. Researchers are developing a prototype of the world's first prosthetic 'intelligent' liner with integrated pressure sensors, which could be available to NHS patients in as little as three years.
Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.
An experimental procedure marks the launch of a research study approved by the Food and Drug Administration in January. The breakthrough technology could save the lives of thousands of people with heart valve disease who have no other treatment options. In a new clinical trial the first U.S. patient has received a heart valve implant without open-heart surgery.
› Verified 3 days ago
| Entity Name | Jaime Elizabeth Medvene Phd A Professional Psychological Corpora |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306084272 PECOS PAC ID: 7911063201 Enrollment ID: O20090312000135 |
News Archive
A new device could help to relieve the pain and discomfort experienced by thousands of amputees as a result of poorly fitting replacement lower limbs. Researchers are developing a prototype of the world's first prosthetic 'intelligent' liner with integrated pressure sensors, which could be available to NHS patients in as little as three years.
Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.
An experimental procedure marks the launch of a research study approved by the Food and Drug Administration in January. The breakthrough technology could save the lives of thousands of people with heart valve disease who have no other treatment options. In a new clinical trial the first U.S. patient has received a heart valve implant without open-heart surgery.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Gene Watson, PSYD 30200 Agoura Rd Ste 190, Agoura Hills, CA 91301-5431 Ph: (818) 981-7845 | Christopher Gene Watson, PSYD 30200 Agoura Rd Ste 190, Agoura Hills, CA 91301-5431 Ph: (818) 981-7845 |
News Archive
A new device could help to relieve the pain and discomfort experienced by thousands of amputees as a result of poorly fitting replacement lower limbs. Researchers are developing a prototype of the world's first prosthetic 'intelligent' liner with integrated pressure sensors, which could be available to NHS patients in as little as three years.
Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.
An experimental procedure marks the launch of a research study approved by the Food and Drug Administration in January. The breakthrough technology could save the lives of thousands of people with heart valve disease who have no other treatment options. In a new clinical trial the first U.S. patient has received a heart valve implant without open-heart surgery.
› Verified 3 days ago
Dr. Laura Lapiana, PSY.D. Psychologist Medicare: May Accept Medicare Assignments Practice Location: 28348 Roadside Dr Ste 201, Agoura Hills, CA 91301 Phone: 310-924-1761 Fax: 818-699-6053 | |
Dr. Shelley Showalter, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 30495 Canwood St Ste 101, Agoura Hills, CA 91301 Phone: 818-707-7366 | |
Alan D. Price, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 30423 Canwood St Ste 138, Agoura Hills, CA 91301 Phone: 818-707-7366 | |
Bahareh Talei, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 30125 Agoura Rd Ste 2b, Agoura Hills, CA 91301 Phone: 818-307-0741 Fax: 818-394-6409 | |
Asamau Denise Ojarigi, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 28240 Agoura Rd Ste 101, Agoura Hills, CA 91301 Phone: 818-584-6113 | |
Lisa Glassman, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 28310 Roadside Dr, Agoura Hills, CA 91301 Phone: 818-835-1614 | |
Shannon M Dobbs, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 28310 Roadside Dr Ste 203, Agoura Hills, CA 91301 Phone: 310-428-2431 |